General Information of the Protein
Protein ID
PT01317
Protein Name
Serine/threonine-protein kinase PAK 4
Secondarily
Protein Name
p21-activated kinase 4
Gene Name
PAK4
Secondarily
Gene Name
KIAA1142
Sequence
MFGKRKKRVEISAPSNFEHRVHTGFDQHEQKFTGLPRQWQSLIEESARRPKPLVDPACITSIQPGAPKTIVRGSKGAKDGALTLLLDEFENMSVTRSNSLRRDSPPPPARARQENGMPEEPATTARGGPGKAGSRGRFAGHSEAGGGSGDRRRAGPEKRPKSSREGSGGPQESSRDKRPLSGPDVGTPQPAGLASGAKLAAGRPFNTYPRADTDHPSRGAQGEPHDVAPNGPSAGGLAIPQSSSSSSRPPTRARGAPSPGVLGPHASEPQLAPPACTPAAPAVPGPPGPRSPQREPQRVSHEQFRAALQLVVDPGDPRSYLDNFIKIGEGSTGIVCIATVRSSGKLVAVKKMDLRKQQRRELLFNEVVIMRDYQHENVVEMYNSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIAAVCLAVLQALSVLHAQGVIHRDIKSDSILLTHDGRVKLSDFGFCAQVSKEVPRRKSLVGTPYWMAPELISRLPYGPEVDIWSLGIMVIEMVDGEPPYFNEPPLKAMKMIRDNLPPRLKNLHKVSPSLKGFLDRLLVRDPAQRATAAELLKHPFLAKAGPPASIVPLMRQNRTR
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
STE protein kinase group
>
STE protein kinase STE20 family
>
STE protein kinase PAKB subfamily
Function
Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, growth, proliferation or cell survival. Activation by various effectors including growth factor receptors or active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates and inactivates the protein phosphatase SSH1, leading to increased inhibitory phosphorylation of the actin binding/depolymerizing factor cofilin. Decreased cofilin activity may lead to stabilization of actin filaments. Phosphorylates LIMK1, a kinase that also inhibits the activity of cofilin. Phosphorylates integrin beta5/ITGB5 and thus regulates cell motility. Phosphorylates ARHGEF2 and activates the downstream target RHOA that plays a role in the regulation of assembly of focal adhesions and actin stress fibers. Stimulates cell survival by phosphorylating the BCL2 antagonist of cell death BAD. Alternatively, inhibits apoptosis by preventing caspase-8 binding to death domain receptors in a kinase independent manner. Plays a role in cell-cycle progression by controlling levels of the cell-cycle regulatory protein CDKN1A and by phosphorylating RAN.
    Show/Hide
Uniprot ID
Primary ID:
O96013

Secondarily ID:
B4DGG6
Q8N4E1
Q8NCH5
Q8NDE3
Q9BU33
Q9ULS8
    Show/Hide
Ensembl ID
ENSG00000130669
HGNC ID
HGNC:16059
Subcellular Location
Cytoplasm
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000006 , HEK293
Compound ID Compound Name Compound Formula
CP0388695
(3S)-N-tert-butyl-3-[(8-chloro-11-ethyl-3-fluoro-5H-benzo[b][1,4]benzodiazepin-6-ylidene)amino]pyrrolidine-1-carboxamide
   Show/Hide
C24H29ClFN5O
 1
1
Kd > 40000 nM
   TI
   LI
   LO
   TS
CP0392297
tert-butyl (3S)-3-[(8-chloro-11-ethyl-3-fluoro-5H-benzo[b][1,4]benzodiazepin-6-ylidene)amino]pyrrolidine-1-carboxylate
   Show/Hide
C24H28ClFN4O2
 1
1
Kd > 40000 nM
   TI
   LI
   LO
   TS
CP0408233
8-chloro-11-ethyl-3-fluoro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzodiazepine
   Show/Hide
C20H22ClFN4
 1
1
Kd > 40000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0028071
N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide
   Show/Hide
C25H30N8OS
 11
1 EC50 < 3.9 nM
2 IC50 = 15 nM
3 IC50 = 18 nM
4 IC50 = 18.7 nM
5 IC50 = 24 nM
6 IC50 = 24.2 nM
7 IC50 = 38 nM
8 Kd = 2.7 nM
9 Ki = 15 nM
10 Ki = 20 nM
11 Ki = 36 nM
CP0414544
2-N-(1H-indazol-5-yl)-4-N-[2-(1H-indol-3-yl)ethyl]-6-methoxy-1,3,5-triazine-2,4-diamine
   Show/Hide
C21H20N8O
 1
1 IC50 = 790 nM
Clinical Information about the Protein
Target 1 ( PAK-4 protein kinase (PAK4) )
Target Type Clinical trial Target
Disease 2 Target-related Diseases  2
1 Non-hodgkin lymphoma [ICD-11: 2B33.5]
2 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 KPT-9274 Phase 1
Non-hodgkin lymphoma
2 PF-3758309 Phase 1
Solid tumour/cancer